Outcome of the Board meeting for followings: 1. Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026, including the Statement of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kimia Biosciences reported audited standalone financial results for FY2026. Revenue from operations declined to ₹11,488.38 Lakhs from ₹11,892.08 Lakhs in FY2025 (approximately 3.4% YoY decline). Profit before tax fell to ₹846.01 Lakhs (down from ₹1,363.42 Lakhs), and profit after tax was ₹743.37 Lakhs versus ₹961.24 Lakhs in the prior year (around 22.7% decline). EPS stood at ₹1.64 per share. The auditors issued an unmodified clean opinion with no going concern doubts. Key audit matters focused on revenue recognition under Ind AS 115 and R&D expenditure accounting—the company changed its treatment by reclassifying certain R&D costs previously expensed to intangible assets where recognition criteria were met. No cash losses were incurred. Preference share capital of ₹8 Crores was redeemed during the year. Working capital limits of ₹29.60 Crores are sanctioned from Kotak Mahindra Bank.
The stock may face pressure due to revenue and profit decline. However, the clean audit opinion and maintained profitability provide some support. The change in R&D accounting treatment is worth monitoring as it impacts how expenses are recognized.